The Food and Drug Administration's Safety Surveillance of Adverse Event Cases Involving Cannabinoid Hemp Products, 2019–2023.

Authors: Wolf, Lisa, Hines, Michelle, Ou, Oliver, Wolpert, Beverly, Nolan, Nichole, Kenez, Stephanie, Taylor, Cassandra

Source: American Journal of Public Health; 2024 Suppl 8, Vol. 114, pS664-S672, 9p

Subject Terms: CANNABIDIOL, LABELS, DRUG side effects, PATIENT safety, DESCRIPTIVE statistics, PEDIATRICS, ENVIRONMENTAL exposure, HEMP, CASE studies, CANNABINOIDS

Company/Entity: UNITED States. Food & Drug Administration

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity

Authors: Ou, Oliver, Huppi, Konrad, Chakka, Sirisha, Gehlhaus, Kristen, Dubois, Wendy, Patel, Jyoti, Chen, Jinqiu, Mackiewicz, Mark, Jones, Tamara L., Pitt, Jason J., Martin, Scott E., Goldsmith, Paul, Simmons, John K., Mock, Beverly A., Caplen, Natasha J. ^*

Source: In Cancer Letters 28 November 2014 354(2):336-347

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.